key: cord-0992912-3pzifv85
authors: Prabhu, Sandeep; Poongulali, Selvamuthu; Kumarasamy, Nagalingeswaran
title: Impact of COVID-19 on people with HIV: A Review
date: 2020-10-15
journal: J Virus Erad
DOI: 10.1016/j.jve.2020.100019
sha: d976b7b869a1d85809cb182415c953400acc81cd
doc_id: 992912
cord_uid: 3pzifv85

There is great concern about the impact of COVID-19 among the nearly 40 million people living with HIV (PLWH) worldwide. In this review, we surveyed current literature and found no evidence of higher prevalence of COVID-19 among PLWH but equivocal data on increased mortality and worse clinical outcomes. Having HIV does not confer protection against severe manifestations of COVID-19. Several studies looking at antiretroviral drugs against HIV to treat SARS-CoV-2 have shown no mortality benefit. Thus, there is no indication to change ART regimens among virologically suppressed PLWH to prevent COVID-19. HIV care delivery has been adversely impacted in several countries during this pandemic but has created an opportunity for accelerating effective strategies like multi-month ART. Decentralizing HIV care in low-resource settings and incorporating telemedicine in high-resource settings will be critical in mitigating shocks to healthcare systems in the future.

As of August 26, 2020, over 24 million people worldwide have been diagnosed with COVID-19, the disease caused by the novel coronavirus (i.e., SARS-CoV-2). Of the nearly 40 million people living with HIV (PLWH) worldwide, most live in countries with poor healthcare infrastructure and the majority are over age 50 in several countries. Advanced age and coexisting chronic diseases, such as hypertension, diabetes, and obesity are associated with severe manifestations and higher mortality from COVID-19, putting many PLWH at increased risk [1] . Alarmingly, two of the three countries with the highest number of HIV infections-South Africa and India-are also among the countries with the highest COVID-19 burdens [2].

J o u r n a l P r e -p r o o f individuals at a single hospital in London had a significantly higher odds ratio of being hospitalized with COVID-19 than non-Black individuals (OR 12.2; 95% CI [1.62, 92] ) [10] .

In the VACS, Black and Latino veterans were 70% and 40% more likely than Caucasians to contract COVID-19, independent of HIV status, respectively. The reasons for this are multifactorial and include a higher prevalence of comorbidities, increased occupational exposure, and other socioeconomic factors, which have been well described elsewhere [11] .

Several small studies have noted that COVID-19 mortality among PLWH does not differ from the general population. A case-control study in New York City that compared 88 PLWH with COVID-19 and matched them to individuals without HIV-1 infection on age, sex, race/ ethnicity, and week of infection found no difference in need for mechanical ventilation or mortality [12] . No difference in hospitalization, ICU admission, intubation, or death by HIV status was noted in the Veterans Aging Cohort Study (VACS) [5] . Similarly, Lee, et al. found no mortality difference by HIV status and even noted that that individuals with HIV were more likely to show clinical improvement/ be discharged within 28 days of admission [13] .

Evidence of significantly increased COVID-19 mortality risk among PLWH comes from a province wide cohort of individuals accessing public healthcare in Western Cape, South 7 the PLWH in the same sample currently have or have had TB. While these results from the Western Cape are from a pre-print and not yet peer reviewed, they are compelling due to the magnitude of effect seen as well as the large sample size of individuals. However, the external validity of these findings in settings where HIV and TB are far less common is unclear.

The data from the ISARIC database, consisting of 53,992 individuals with COVID-19, found that hospitalized PLWH with COVID-19 had a 63% higher mortality than their HIV negative counterparts, after adjusting for age, ethnicity, comorbidities, and disease severity when they presented to the hospital [8] . Similarly, results from the OpenSAFELY dataset, consisting of clinical data from hundreds of primary care practices through the UK, found a more than twofold increase in mortality among PLWH with COVID-19 compared to those without HIV-1 infection (HR 2.30; 95% CI [1.55, 3.41]) after adjusting for age, ethnicity, and several comorbidities [14] . Notably, both studies lack data on HIV-related parameters such as antiretroviral therapy (ART) use, HIV-1 viral load, CD4 T cell count, and prior opportunistic infections, all of which are important confounders. While both studies note that over 90% of individuals diagnosed with HIV-1 receive ART, it is impossible to know if the small number of PLWH constitutes a representative sample case-series in the UK. Consequently, we interpret this data with caution.

The correlation between COVID-19 mortality among PLWH and other comorbidities is noted in multiple studies. Vizcarra, et al. noted a higher prevalence of comorbidities among PLWH with COVID-19 than in individuals without HIV (63% vs. 38%; p<0.01) [3] . 7 of 9 PLWH with COVID-19 died in a case series from the Bronx; none of the individuals had >50 copies of HIV-1 RNA, but everyone aged >50 in this case series died [16] . Are comorbidities among PLWH the drivers of poor outcomes from COVID-19 rather than HIV itself? Questions about J o u r n a l P r e -p r o o f 8 whether comorbidities are confounders or effect measure modifiers are important and still unclear [17, 18] .

Larger prospective studies are required to elucidate this further and assess if a synergistic effect between comorbidities and HIV exists. Currently published studies mostly feature individuals with undetectable HIV-1 viral loads, making it challenging to generalize to those with poorly controlled HIV [7, 10, 19, 20] . We call for more work on broader samples of PLWH (including those with advanced disease).

J o u r n a l P r e -p r o o f Pathogenesis Do PLWH with COVID-19 have worse outcomes than the general population? There are two contrasting hypotheses for this question. The first one, from Mascolo and colleagues, hypothesizes that relative immunosuppression from HIV may make PLWH more susceptible to contracting COVID-19, but lymphopenia may protect against severe manifestations of COVID-19 due to an inability to mount an overactive T cell response [21] . The other one draws from prior studies showing that HIV-1 infection is characterized by a chronically elevated inflammatory state, which when combined with the cytokine storm seen in severe COVID-19, should theoretically worsen outcomes [22] . Two case-series and several observational studies provide further insights. individuals who died had lower nadir lymphocyte counts and higher levels of inflammatory markers (C-reactive protein, IL-6, and IL-8) than those who survived [23] . In contrast, Patel, et al. noted a higher rate of intubation and death among PLWH who were virally suppressed compared to those who were not and an increased likelihood of intubation among PLWH with higher CD4 T cell counts [24] . Lee, et al. found that PLWH in one London hospital were discharged more quickly than their matched HIV-1 negative counterparts [13] .

Clearly, the evidence is equivocal. [25, 26] . Conversely, it is important that atypical clinical presentations of HIV-1 remain on the differential diagnosis and the individuals are offered HIV-1 testing when appropriate.

It remains a matter of debate how protective antibodies against SARS-CoV-2 are, how long they last, and if they help prevent reinfections. These questions notwithstanding, a single case report suggests a slower rate of protective antibody development against SARS-CoV-2 among individuals with HIV-1 compared to those without. While a case-series from Chongqing of hospitalized patients with COVID-19 (HIV-1 status unknown) reported a median time from start of symptoms to IgG seroconversion of 13 days, a case-report of a PLWH noted that it took several weeks for a patient to develop an IgM antibody response against SARS-CoV-2 [25, 27] . Larger scale studies are needed to confirm if this pattern is confirmed. Furthermore, we do not know if waning antibody titers will still prevent COVID-19 reinfection due to an amnestic response. Until such data is available, guidelines on self-J o u r n a l P r e -p r o o f 11 isolation after COVID-19 diagnosis used for the general population should be followed for PLWH.

PLWH admitted with COVID-19 must continue to receive ART and appropriate OI prophylaxis if CD4 T cell counts decrease. Furthermore, when therapeutics targeting COVID-19 are initiated, clinicians must be cognizant of drug-drug interactions with ART to prevent adverse effects.

There is still much to be gleaned on the natural history of COVID-19 infection in PLWH, with many prospective observational studies underway [28] . Unanswered questions include how the different complications of each infection manifest in HIV-1 and COVID-19 coinfection. For example, hospitalized patients with COVID-19 have a high incidence of venous thromboembolism [29] . PLWH have an elevated inflammatory state, especially with advanced/ uncontrolled disease [22] . Whether this results in drastically adverse outcomes is still unknown. Upcoming studies should incorporate a wide array of PLWH, including those with advanced HIV/ low CD4 T cell counts.

The search for pharmacologic therapies against SARS-CoV-2 has initially largely focused on studying existing drugs targeting other viruses, including antiretroviral agents (ARVs) used to treat HIV. Initial genomic analysis of SARS-CoV-2 has indicated that viral enzymes are similar in sequence to the respective enzymes in SARS and MERS [30] .

Early optimism about protease inhibitors such as lopinavir/ ritonavir (LPV/r) arose from early guidance from Wuhan and prior data suggesting efficacy against SARS and MERS [31] . As seen in Table 1 , the three randomized trials looking at outcomes from LPV/r use in COVID-19 provide no evidence that LPV/r improves clinical outcomes among hospitalized patients with COVID-19 and may even lead to clinical progression. [32] . The investigator is leading the EPICOS trial in Spain looking at whether tenofovir, either in conjunction with emtricitabine or both emtricitabine and hydroxychloroquine, can prevent COVID-19 among healthcare workers [33] . We look forward to seeing the results of this trial noting that the current evidence for NRTIs as treatment for COVID-19 is not proven.

In summary, there is currently no indication to change ART regimens among virologically suppressed PLWH to prevent COVID-19. Until new data from ongoing trials emerges, national governments must work to ensure that medications like LPV/r, a second line of treatment for some PLWH, are maintained and not diverted.

J o u r n a l P r e -p r o o f 13 We are concerned that PLWH are being excluded from large phase III studies assessing the efficacy of a SARS-CoV-2 vaccine [34] . Considering the evidence that current ART regimens have no protective effect against COVID-19, we do not see a clinical justification for excluding people with well-controlled HIV-1 when other types of patients with stable medical conditions remain eligible to participate in these studies. This unconscionable exclusion can further reduce access to PLWH, as occurred with Zostavax several years ago, when initial studies on its efficacy excluded virally-suppressed PLWH, who did not obtain insurance coverage until a separate efficacy trial among PLWH was performed [35] . LPV/r arm discontinued on July 4, 2020 due to lack of mortality reduction

Years of progress in HIV testing and treatment are in jeopardy due to the COVID-19 pandemic, which has created unprecedented challenges to HIV care delivery worldwide.

The fear of contracting COVID-19 has led to decreased engagement with care among PLWH in several countries [39] [40] [41] [42] . The reasons for this are unsurprising-people who have faced stigma for decades due to their HIV status and live under the burden of a chronic virus are hesitant to engage in care when the prospect of being infected with another, more deadly virus is real. This fear has even led some to question the safety of going to pharmacies to collect ART [41] .

National lockdowns have also significantly hindered access to care. In Uganda, nationwide public and private transportation suspensions have made distant clinics all but impossible to access for many [40] . Migrant workers in cities have retreated to the rural areas they are from, likely losing access to HIV care in the cities where they lived [42] . Even when people can access clinics, the financial stress from loss of livelihoods make it harder for them to pay for care.

Finally, physical distancing guidelines can exacerbate the high levels of isolation that older individuals with HIV already face [43] . Despite no definitive evidence that PLWH are at higher risk of contracting COVID-19, individuals may fear that they are and result in them presenting late to care. Depression is the second most common mental health disorder (after substance use) among PLWH and constitutes an additional barrier to care [44] . The ongoing pandemic is a significant stressor and likely to worsen the already high prevalence of mental health concerns among PLWH [45] .

The rapidly growing pandemic has strained national healthcare systems worldwide. In Eastern Europe, HIV physicians have been called to care for patients with COVID-19, creating staffing shortages [39] . This has forced some clinics to suspend in-person visits, others to postpone blood tests, and some to solely focus on ART distribution.

Simultaneously, these already overwhelmed clinics are approached by PLWH who previously received their healthcare elsewhere but were unable to return home due to travel restrictions.

These challenges limit the ability of clinics to identify individuals with drug resistance, rapidly diagnose opportunistic infections, and carry out routine blood tests. For high risk individuals who wish to be tested for HIV, this delays linkage to care, making it impossible to "test and treat" in a timely manner. Modelling studies show that even a three-month disruption of ART supply can lead to half a million excessive HIV/AIDS related deaths in Africa alone, erasing years of progress [46] .

The challenges to HIV care mentioned above are simultaneously impacting tuberculosis (TB) care. TB is the leading cause of mortality among PLWH and modelling studies show that even short-term disruptions in TB diagnosis and treatment can lead to increased incidence and mortality for many years to come [47] . One of the major strategies to tackle the spread of COVID-19 has been encouraging 'shelter in place' or home quarantine; prolonged contact at the household level can lead to household transmission of TB, whose long incubation period means we may not see the impact of this on TB incidence for months or years [48] .

Finally, an increased emphasis on COVID-19 should not distract from timely administration of annual influenza and guideline-directed pneumococcal vaccines to PLWH.

Despite such monumental challenges, this pandemic creates the opportunity to accelerate much needed changes in care delivery. Multi-month prescribing has now taken off in several African and Eastern European countries [39, 49] . While this has the obvious drawback of limited viral load/ CD4 monitoring, it provides an opportunity for innovation in point-of-care testing solutions.

Moving forward, countries should work towards maintaining a steady supply of ARVs and anti-TB drugs, especially when exclusively imported. Notably, South Africa did not expand multi-month prescribing due to fears of ART shortages. This is necessary to buffer health systems against external shocks, especially in high HIV/ TB prevalence settings.

Finally, solutions must be tailored in a location-specific manner-telemedicine visits help maintain consistent patient access to their providers in high resource settings [50] . In low resource settings, decentralizing HIV testing will help both increase access to care and offload larger hospitals, which can focus on sicker patients. In Spain, some non-governmental organizations are involved in collecting medications for individuals and delivering them to their homes, which can be particularly effective for elderly individuals who are already at high risk of contracting COVID-19 [41] .

The rapid spread of SARS-CoV-2 globally has created unprecedented challenges to health systems worldwide, making it inevitable that the world will miss the 2020 goal of fewer than 500,000 annual HIV/AIDS related deaths, but a loss of focus on HIV/AIDS programs amidst the global pandemic risks erasing years of progress.

J o u r n a l P r e -p r o o f

Clinical Characteristics of Coronavirus Disease 2019 in China

Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

COVID-19 in the largest US HIV cohort

Polish Scientific AIDS Society Statement on risk of COVID-19 for people living with HIV (PLWH)

Clinical features and outcomes of HIV patients with coronavirus disease 2019

Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO

Clinical Characterisation Protocol UK Protocol: prospective observational study

Do people living with HIV experience greater age advancement than their HIV-negative counterparts?

Hospitalized patients with COVID-19 and HIV: a case series

COVID-19 and Racial/Ethnic Disparities

Covid-19 and People with HIV Infection: Outcomes for Hospitalized Patients

Comparative outcomes in hospital admissions with COVID-19 in people living with HIV and people living without HIV: A retrospective study

HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform

Risk of COVID-19 death among people with HIV: A population cohort analysis from the Western Cape Province, South Africa. National Institute of Communicable Diseases

Clinical features and outcome of HIV/SARS-CoV-2 coinfected patients in The Bronx

HIV and SARS-CoV-2: Intersecting Epidemics with Many Unknowns

Clinical characteristics, comorbidities and outcomes among persons with HIV hospitalized with coronavirus disease

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

Outcomes among HIV-positive patients hospitalized with COVID-19

Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better

Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers

Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV

Clinical outcomes by HIV serostatus, CD4 count, and viral suppression among people hospitalized with COVID-19 in the

One case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a low CD4(+) T-cell count

Pneumocystis Jirovecii Pneumonia and SARS-CoV-2 Co-Infection in newly diagnosed HIV-1

Antibody responses to SARS-CoV-2 in patients with COVID-19

COVID-19 in Patients With HIV. NLM Identifier: NCT04333953. ClinicaltrialsGov 2020

Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far?

Therapeutic options for the 2019 novel coronavirus

Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment

Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy

Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19

Groups protest exclusion of HIV-infected people from coronavirus vaccine trials

Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial

Solidarity" clinical trial for COVID-19 treatments. World Health Organization 2020

HIV care in times of the COVID-19 crisis -Where are we now in Central and Eastern Europe?

Everything is a Mess": How COVID-19 is Impacting Engagement with HIV Testing Services in Rural Southwestern Uganda

The Virus that Changed Spain: Impact of COVID-19 on People with HIV

COVID-19, HIV, and Migrant Workers: The Double Burden of the Two Viruses

The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective

HIV and depression: 2008 review and update

Mental health and psychosocial considerations during the COVID-19 outbreak

Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models 2020

The potential impact of the COVID-19 pandemic on tuberculosis: a modelling analysis

Impact of the COVID-19 Pandemic on Tuberculosis Control: An Overview

Rapid adaptation of HIV differentiated service delivery program design in response to COVID-19: Results from 14 countries in sub-Saharan Africa

Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.J o u r n a l P r e -p r o o f